Literature DB >> 34028567

Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma.

Lulu Liu1, Ruyi Zhang1, Jingwen Deng2,3, Xiaomeng Dai1, Xudong Zhu1, Qihan Fu1, Hangyu Zhang1, Zhou Tong1, Peng Zhao1, Weijia Fang1, Yi Zheng4,5, Xuanwen Bao6.   

Abstract

Liver cancer accounts for 6% of all malignancies causing death worldwide, and hepatocellular carcinoma (HCC) is the most common histological type. HCC is a heterogeneous cancer, but how the tumour microenvironment (TME) of HCC contributes to the progression of HCC remains unclear. In this study, we investigated the immune microenvironment by multiomics analysis. The tumour immune infiltration characteristics of HCC were determined at the genomic, epigenetic, bulk transcriptome and single-cell levels by data from The Cancer Genome Atlas portal and the Gene Expression Omnibus (GEO). An epigenetic immune-related scoring system (EIRS) was developed to stratify patients with poor prognosis. SPP1, one gene in the EIRS system, was identified as an immune-related predictor of poor survival in HCC patients. Through receptor-ligand pair analysis in single-cell RNA-seq, SPP1 was indicated to mediate the crosstalk between HCC cells and macrophages via SPP1-CD44 and SPP1-PTGER4 association. In vitro experiments further validate SPP1 can trigger the polarization of macrophages to M2-phenotype tumour-associated macrophages (TAMs).
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Crosstalk; Hepatocellular carcinoma (HCC); Prognosis; SPP1; Tumour microenvironment (TME); Tumour-associated macrophages (TAMs)

Mesh:

Substances:

Year:  2021        PMID: 34028567     DOI: 10.1007/s00262-021-02967-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  2 in total

1.  The high expression of Fractalkine results in a better prognosis for colorectal cancer patients.

Authors:  Mitsuhiko Ohta; Fumiaki Tanaka; Hiroshi Yamaguchi; Noriaki Sadanaga; Hiroshi Inoue; Masaki Mori
Journal:  Int J Oncol       Date:  2005-01       Impact factor: 5.650

2.  Role of plasma osteopontin as a biomarker in locally advanced breast cancer.

Authors:  Pieter H Anborgh; Laura Br Caria; Ann F Chambers; Alan B Tuck; Larry W Stitt; Muriel Brackstone
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

  2 in total
  6 in total

Review 1.  Mapping and Validation of scRNA-Seq-Derived Cell-Cell Communication Networks in the Tumor Microenvironment.

Authors:  Kate Bridges; Kathryn Miller-Jensen
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

Review 2.  The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective.

Authors:  Sofia Zanotti; Gina F Boot; Mairene Coto-Llerena; John Gallon; Gabriel F Hess; Savas D Soysal; Otto Kollmar; Charlotte K Y Ng; Salvatore Piscuoglio
Journal:  Front Med (Lausanne)       Date:  2022-06-24

3.  Single-Cell RNA-seq Analysis Reveals Dysregulated Cell-Cell Interactions in a Tumor Microenvironment Related to HCC Development.

Authors:  Zhenhao Liu; Siwen Zhang; Jian Ouyang; Dan Wu; Lanming Chen; Wen Zhou; Lu Xie
Journal:  Dis Markers       Date:  2022-05-18       Impact factor: 3.464

4.  Single-Cell Transcriptomic Analysis Reveals Macrophage-Tumor Crosstalk in Hepatocellular Carcinoma.

Authors:  Yunhe Liu; Lin Zhang; Xinyi Ju; Sheng Wang; Jingbo Qie
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

5.  Evaluating the role of IDO1 macrophages in immunotherapy using scRNA-seq and bulk-seq in colorectal cancer.

Authors:  Xingwu Liu; Guanyu Yan; Boyang Xu; Han Yu; Yue An; Mingjun Sun
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

6.  The role of hypoxia-related genes in TACE-refractory hepatocellular carcinoma: Exploration of prognosis, immunological characteristics and drug resistance based on onco-multi-OMICS approach.

Authors:  Xuelian Cheng; Jingjing Li; Limei Feng; Songwei Feng; Xiao Wu; Yongming Li
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.